Product Watch: Swift Biosciences, Bio-Rad, and Exiqon | GenomeWeb

Swift Biosciences recently launched myT KRAS, the third product in its myT Primer menu of reagents to detect cancer mutations.

The myT KRAS kit provides 1 percent sensitivity for seven key mutations in codons 12 and 13 with little or no breakthrough from wild type, resulting in an assay with a definitive yes/no answer over a wide dynamic range, Swift said.

The assay works well with both frozen and formalin-fixed, paraffin-embedded samples, and each package includes sufficient reagents to test 30 samples, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.